Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12857/115798
Title: Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer
Authors: Moreno, Lucas
Casanova, Michela
Chisholm, Julia C
Berlanga, Pablo
Chastagner, Pascal B
Baruchel, Sylvain
Amoroso, Loredana
Gallego Melcón, Soledad
Gerber, Nicolas U
Bisogno, Gianni 
Fagioli, Franca
Geoerger, Birgit
Glade Bender, Julia L
Aerts, Isabelle
Bergeron, Christophe
Hingorani, Pooja
Elias, Ileana
Simcock, Mathew
Ferrara, Stefano
Le Bruchec, Yvan
Slepetis, Ruta
Chen, Nianhang
Vassal, Gilles
Keywords: Ewing sarcoma;Neuroblastoma;Paediatric;Rhabdomyosarcoma;Solid tumour;nab-paclitaxel
Keywords Plus: SOLVENT-BASED PACLITAXEL;ALBUMIN-BOUND PACLITAXEL;CREMOPHOR-FREE;BREAST-CANCER;GROUP TRIAL;III TRIAL;SURVIVAL;DOCETAXEL;INSTITUTE;INFUSION
Mesh headings: Albumins;Antineoplastic Agents, Phytogenic;Neoplasms;Paclitaxel
Secondary Mesh headings: Adolescent;Age Factors;Canada;Child;Child, Preschool;Drug Administration Schedule;Drug Dosage Calculations;Europe;Female;Humans;Male;Maximum Tolerated Dose;Time Factors;Treatment Outcome;United States
Issue Date: 2018
Publisher: ELSEVIER SCI LTD
Journal: European journal of cancer (Oxford, England : 1990) 
Abstract: 
nab-Paclitaxel has demonstrated efficacy in adults with solid tumours and preclinical activity in paediatric solid tumour models. Results from phase I of a phase I/II study in paediatric patients with recurrent/refractory solid tumours treated with nab-paclitaxel are reported.
URI: http://hdl.handle.net/20.500.12857/115798
ISSN: 09598049
DOI: 10.1016/j.ejca.2018.05.002
Appears in Collections:Articles

Show full item record

PubMed Central
Citations 50

5
Last Week
0
Last month
2
checked on May 2, 2021

SCOPUSTM   
Citations 5

9
checked on Sep 1, 2020

WEB OF SCIENCETM
Citations

11
checked on Dec 4, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.